ATRX and central nervous system cancer: A receiver operating characteristic curve analysis indicated that HOXA5, PTPN2, WT1, HOXD10, POSTN, ADAMDEC1 and MYBPH had significant prognostic value for the survival of ATRX-wt glioma patients (AUC = 0.84, 0.81, 0.79, 0.91, 0.80, 0.79 and 0.85, respectively) (Figure 9C).